Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer.

Walker EJ, Simko JP, Nakakura EK, Ko AH.

J Gastrointest Oncol. 2014 Dec;5(6):E88-95. doi: 10.3978/j.issn.2078-6891.2014.051.

2.

Cancer review: Cholangiocarcinoma.

Ghouri YA, Mian I, Blechacz B.

J Carcinog. 2015 Feb 23;14:1. doi: 10.4103/1477-3163.151940. eCollection 2015. Review.

3.

Concurrent chemoradiation for resected gall bladder cancers and cholangiocarcinomas.

Fareed MM, DeMora L, Esnaola NF, Denlinger CS, Karachristos A, Ross EE, Hoffman J, Meyer JE.

J Gastrointest Oncol. 2018 Aug;9(4):762-768. doi: 10.21037/jgo.2018.05.09.

4.

Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.

Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, Mobley CM, Saharia A, Victor DW, Nguyen DT, Graviss EA, Kaseb AO, McFadden RS, Aloia TA, Conrad C, Li XC, Monsour HP, Gaber AO, Vauthey JN, Ghobrial RM; Methodist–MD Anderson Joint Cholangiocarcinoma Collaborative Committee (MMAJCCC).

Lancet Gastroenterol Hepatol. 2018 May;3(5):337-348. doi: 10.1016/S2468-1253(18)30045-1. Epub 2018 Mar 13. Erratum in: Lancet Gastroenterol Hepatol. 2018 Jun;3(6):e3.

PMID:
29548617
5.

Chemotherapy for cholangiocarcinoma: An update.

Ramírez-Merino N, Aix SP, Cortés-Funes H.

World J Gastrointest Oncol. 2013 Jul 15;5(7):171-6. doi: 10.4251/wjgo.v5.i7.171.

6.

Future directions in the treatment of cholangiocarcinoma.

Zhu AX.

Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):355-61. doi: 10.1016/j.bpg.2015.02.010. Epub 2015 Feb 19. Review.

PMID:
25966434
7.

A review of the clinical diagnosis and therapy of cholangiocarcinoma.

Yao D, Kunam VK, Li X.

J Int Med Res. 2014 Feb;42(1):3-16. doi: 10.1177/0300060513505488. Epub 2013 Dec 23. Review.

PMID:
24366497
8.

Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.

Abdel-Rahman O, Elsayed Z, Elhalawani H.

Cochrane Database Syst Rev. 2018 Apr 6;4:CD011746. doi: 10.1002/14651858.CD011746.pub2. Review.

PMID:
29624208
9.

A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract.

Czito BG, Hong TJ, Cohen DP, Petros WP, Tyler DS, Pappas TN, Yu D, Lee CG, Lockhart AC, Morse MA, Fernando N, Hurwitz HI.

Cancer Invest. 2006 Feb;24(1):9-17.

PMID:
16466986
11.

Transplantation for cholangiocarcinoma.

Masuoka HC, Rosen CB.

Clin Liver Dis. 2011 Nov;15(4):699-715. doi: 10.1016/j.cld.2011.08.004. Review.

PMID:
22032524
12.

Neoadjuvant therapy and liver transplantation for hilar cholangiocarcinoma: is pretreatment pathological confirmation of diagnosis necessary?

Rosen CB, Darwish Murad S, Heimbach JK, Nyberg SL, Nagorney DM, Gores GJ.

J Am Coll Surg. 2012 Jul;215(1):31-8; discussion 38-40. doi: 10.1016/j.jamcollsurg.2012.03.014. Epub 2012 May 22.

PMID:
22621893
13.

Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinoma.

Brunner TB, Eccles CL.

Strahlenther Onkol. 2010 Dec;186(12):672-80. doi: 10.1007/s00066-010-2161-y. Epub 2010 Nov 30. Review.

PMID:
21136029
14.

Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial.

Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klümpen HJ, Lohse AW, Nashan B, Primrose J, Schrum S, Shannon J, Vettorazzi E, Wege H.

BMC Cancer. 2015 Jul 31;15:564. doi: 10.1186/s12885-015-1498-0.

15.

Cholangiocellular Carcinoma.

Vogel A, Saborowski A.

Digestion. 2017;95(3):181-185. doi: 10.1159/000454763. Epub 2017 Mar 14.

16.

Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.

Rajagopalan MS, Heron DE, Wegner RE, Zeh HJ, Bahary N, Krasinskas AM, Lembersky B, Brand R, Moser AJ, Quinn AE, Burton SA.

Radiat Oncol. 2013 Oct 31;8:254. doi: 10.1186/1748-717X-8-254.

17.

What is the role of neoadjuvant chemotherapy, radiation, and adjuvant treatment in resectable esophageal cancer?

Altorki N, Harrison S.

Ann Cardiothorac Surg. 2017 Mar;6(2):167-174. doi: 10.21037/acs.2017.03.16.

18.

Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.

Kuerer HM, Newman LA, Buzdar AU, Dhingra K, Hunt KK, Buchholz TA, Binkley SM, Strom EA, Ames FC, Ross MI, Feig BW, McNeese MD, Hortobagyi GN, Singletary SE.

Cancer J Sci Am. 1998 Jul-Aug;4(4):230-6.

PMID:
9689981
19.

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.

Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, Jang JS, Jeung HC, Kang JH, Lee HW, Shin DB, Kang HJ, Sun JM, Park JO, Park YS, Kang WK, Lim HY.

Lancet Oncol. 2012 Feb;13(2):181-8. doi: 10.1016/S1470-2045(11)70301-1. Epub 2011 Dec 20. Erratum in: Lancet Oncol. 2012 Feb;13(2):e49. Chang, Joung Soon [corrected to Jang, Joung Soon].

PMID:
22192731
20.

Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins.

Glazer ES, Liu P, Abdalla EK, Vauthey JN, Curley SA.

J Gastrointest Surg. 2012 Sep;16(9):1666-71. doi: 10.1007/s11605-012-1935-1. Epub 2012 Jul 10.

Supplemental Content

Support Center